Puma Biotechnology, Inc. (PBYI)
Largest Insider Buys in Sector
PBYI Stock Price History Chart
PBYI Stock Performance
About Puma Biotechnology, Inc.
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive …
Insider Activity of Puma Biotechnology, Inc.
Over the last 12 months, insiders at Puma Biotechnology, Inc. have bought $0 and sold $1.1M worth of Puma Biotechnology, Inc. stock.
On average, over the past 5 years, insiders at Puma Biotechnology, Inc. have bought $0 and sold $1.05M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 56 shares for transaction amount of $4,619 was made by BRYCE RICHARD PAUL (SR VP, CLINICAL RESEARCH & DEV) on 2014‑04‑11.
List of Insider Buy and Sell Transactions, Puma Biotechnology, Inc.
| 2024-08-12 | Sale | director | 23,358 0.0487% | $3.49 | $81,466 | -25.07% | ||
| 2024-07-17 | Sale | President and CEO | 21,920 0.0461% | $3.70 | $81,128 | -26.58% | ||
| 2024-07-17 | Sale | Chief Financial Officer | 4,156 0.0087% | $3.70 | $15,382 | -26.58% | ||
| 2024-07-17 | Sale | See Remarks | 3,637 0.0076% | $3.70 | $13,461 | -26.58% | ||
| 2024-07-17 | Sale | Chief Commercial Officer | 2,598 0.0055% | $3.70 | $9,615 | -26.58% | ||
| 2024-07-02 | Sale | President and CEO | 18,885 0.0408% | $3.27 | $61,726 | 0.00% | ||
| 2024-07-02 | Sale | Chief Financial Officer | 5,295 0.0114% | $3.27 | $17,307 | 0.00% | ||
| 2024-07-02 | Sale | See Remarks | 4,349 0.0094% | $3.27 | $14,215 | 0.00% | ||
| 2024-07-02 | Sale | Chief Commercial Officer | 6,051 0.0131% | $3.27 | $19,778 | 0.00% | ||
| 2024-06-13 | Sale | director | 9,900 0.02% | $3.39 | $33,528 | -15.06% | ||
| 2024-06-13 | Sale | director | 11,000 0.0222% | $3.37 | $37,096 | -15.06% | ||
| 2024-06-13 | Sale | director | 22,000 0.0439% | $3.34 | $73,467 | -15.06% | ||
| 2024-06-13 | Sale | director | 27,000 0.0537% | $3.33 | $89,902 | -15.06% | ||
| 2024-06-13 | Sale | director | 27,000 0.0537% | $3.33 | $89,818 | -15.06% | ||
| 2024-01-03 | Sale | President and CEO | 41,396 0.0889% | $4.49 | $185,698 | +0.12% | ||
| 2024-01-03 | Sale | Chief Financial Officer | 15,682 0.0337% | $4.49 | $70,348 | +0.12% | ||
| 2024-01-03 | Sale | See Remarks | 8,358 0.018% | $4.49 | $37,493 | +0.12% | ||
| 2024-01-03 | Sale | Chief Commercial Officer | 12,956 0.0278% | $4.49 | $58,119 | +0.12% | ||
| 2024-01-03 | Sale | Chief Scientific Officer | 7,733 0.0166% | $4.49 | $34,689 | +0.12% | ||
| 2023-12-04 | Sale | Chief Scientific Officer | 280 0.0006% | $3.76 | $1,053 | +8.81% |
Insider Historical Profitability
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 10 percent owner | 3696580 7.5369% | $3.03 | 21 | 9 | +122.06% |
| Malley Thomas | director | 156551 0.3192% | $3.03 | 4 | 0 | +51.73% |
| BRYCE RICHARD PAUL | SEE REMARKS | 121662 0.2481% | $3.03 | 2 | 39 | +159.55% |
Institutional Investor Ownership
| The Vanguard Group | $18.5M | 7.24 | 3.49M | -8.18% | -$1.65M | <0.0001 | |
| Millennium Management LLC | $16.79M | 6.57 | 3.17M | +0.1% | +$17,034.20 | 0.01 | |
| Frazier Life Sciences Management L P | $14.93M | 5.84 | 2.82M | New | +$14.93M | 0.67 | |
| Acadian Asset Management | $10.37M | 4.06 | 1.96M | +2.05% | +$207,896.13 | 0.04 | |
| Renaissance Technologies | $9.17M | 3.59 | 1.73M | +3.36% | +$297,863.61 | 0.02 |